cefuroxime (zinacef) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic. Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefuroxime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infection: Enterobacter spp., Escherichia coli, Klebsiella spp., Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Cefuroxime is indicated for the treatment of patients with septicemia, meningitis, gonorrhea, lower respiratory tract, urinary tract, skin and skin-structure, bone and joint infections caused by susceptible strains of the designated organisms.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.4767 - $3.4644

Australia

$0.5586 - $9.5284
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

640/359 | (6r,7r)-3-[(carbamoyloxy)methyl]-7-{[(2z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | acetoxyethylcefuroxime | altacef | biofuroxim | britacef | cci 15641 | cci-15641 | cefaloxime | cefasyn | cefazine | ceftin | cefuoxim | cefurax | cefuroxim | cefuroxime | cefuroxime 1-acetoxyethyl ester | cefuroxime acid | cefuroxime axetil | cefuroxime pivoxetil | cefuroxime sodium | cefuroxime sodium salt | cefuroximine | cefuroximo | cefuroximum | cephuroxime | kefurox | oraxim | zinacef | zinacef danmark | zinnat

Organizations (108)

Research & Development (86)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (2)


 

Bacterial Infections (approved 1983)

Infections

Experimental Indications - Clinical Trial Phases 1-4 (27)


 

Appendicitis (Phase 4)

Bacteremia (Phase 4)

Bacterial Infections (Phase 4)

Cesarean Section (Phase 4)

Community-Acquired Infections (Phase 4)

Duodenal Ulcer (Phase 3)

Enterobacteriaceae Infections (Phase 3)

Erythema (Phase 4)

General Surgery (Phase 4)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 2)

Infant, Premature (Phase 4)

Infections ()

Intestinal Diseases (Phase 3)

Medicine, Chinese Traditional (Early Phase 1)

Obesity (Phase 4)

Osteoarthritis, Knee (Phase 4)

Pneumonia (Phase 3)

Postoperative Complications (Phase 4)

Respiratory Tract Infections (Early Phase 1)

Signs and Symptoms (Phase 4)

Sinusitis (Phase 2)

Streptococcal Infections (Phase 4)

Surgical Wound Infection (Phase 4)

Urinary Tract Infections (Phase 4)

Wound Infection (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 68
  • # of Trial Organizations: 86

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue